摘要结直肠癌的转化医学研究日益趋向于精准诊治这一目标。精确的分子分型有助于更好地指导临床实践。而目前的结直肠癌分期分型尚不能完全解决临床需求，如：结直肠癌 TNM 分期的Ⅱ期及Ⅲ期对预后估计不足；对于Ⅱ期如何能区分高危与低危不同类型等。欧美等国家已提出了多项结合临床病理表型与分子表型的分子分型方法，具有一定现实意义，有助于推动治疗方案及靶向药物的选择。但目前的研究结果均需临床大样本多中心研究的进一步验证。分子分型从精准医学出发，通过基因组学结合临床各种表型，逐步识别其临床意义，经过进一步完善，必然能用于指导临床，这也是实现精准医学的必然过程。近年来，结直肠癌肝转移处理也有许多新的进展。对结直肠癌Ⅳ期肝转移者，经手术切除肝转移灶后的预后与Ⅲ期结直肠癌近似，但对于初始不可切除的患者，经过转化治疗后，约1／3患者术后6个月内出现早期复发，总生存期较差。为此，应研究建立评估体系，使这一部分患者避免强烈治疗，争取获得更好的生活质量。结直肠癌个体化治疗日益受到重视，体液（液体）标志物是目前研究的热点，包括从周围血及尿液等进行相关标志物检测，临床研究者均有所尝试，涵括了血清蛋白（或多肽）、血浆miRNA以及循环肿瘤细胞（CTC）及循环核酸等检测方法。

abstractsPrecision medicine is becoming the goal of translational research on colorectal cancer. Accurate molecular subtyping contributes to better guidance of clinical practice. The current TNM staging system of colorectal cancer is inadequate in terms of guiding clinical practice , such as the underestimation of prognosis of with stage Ⅱ and Ⅲ colorectal cancer TNM staging, and identification of high-risk and low-risk patients with stageⅡ colorectal cancer. Researchers from Europe and US have proposed a number of molecular subtypings with clinicopathological phenotypes and molecular phenotypes, which has certain practical significance and is beneficial to the choice of treatment regimen and targeted drugs. But the current results of subtyping research require further validations by clinical large scale multi-center trials. Based on precision medicine, molecular subtyping gradually reveals its clinical significance and is optimized through combining genomics with various clinical phenotypes , indicating its guidance for clinical practice, which is the inevitable course of precision medicine accomplishment. In recent years , there have been many new advances in colorectal cancer liver metastasis treatment. The prognosis of colorectal cancer patients undergoing resection of liver metastasis lesion is similar to those with stage Ⅲ. Early recurrence within 6 months after translational treatment and resection occurred in about one third of the patients with initially unresectable liver metastasis , and the overall survival was poor. Thus, an evaluation system should be established in order to avoid the strong therapy and strive for better quality of life in some patients. Individualized treatment for colorectal cancer is emphasized increasingly. Body fluid (peripheral blood and urine) marker detection is a recent research hotspot, including serum protein(polypeptide), plasma miRNA, circulating tumor cells and circulating nucleic acid.